Neural Regeneration Research, 2023 · DOI: https://doi.org/10.4103/1673-5374.355749 · Published: May 1, 2023
Spinal cord injuries (SCI) damage nerves and tissues around the spinal cord, leading to axon and myelin degeneration, causing neuronal impairment, muscle weakness, and atrophy. Protecting neurons and promoting myelin regeneration are vital for functional recovery after SCI. Clemastine, an FDA-approved antihistamine, has shown potential in reducing inflammation, protecting cells, promoting remyelination, and preserving myelin integrity. It may also stimulate oligodendrocyte progenitor cell differentiation into mature oligodendrocytes, which are responsible for myelination. This review discusses SCI pathophysiology and clemastine's role in protecting neurons, myelin, and axons, as well as reducing muscle loss after SCI. Current treatments have limited effectiveness, making clemastine a promising potential therapy.
Clemastine shows promise as a therapeutic treatment for spinal cord injuries by promoting remyelination, protecting neurons, and stimulating muscle fiber growth.
The use of clemastine alongside other therapies and exercise may improve muscle function, mobility, and overall quality of life for individuals with SCI.
Additional research is needed to explore clemastine's mechanisms of action and optimize its therapeutic application for SCI patients.